<DOC>
	<DOCNO>NCT00421317</DOCNO>
	<brief_summary>The scope trial determinate anti-tumoral activity imatinib metastatic ocular melanoma patient .</brief_summary>
	<brief_title>Imatinib Adult Patients With Metastatic Ocular Melanoma</brief_title>
	<detailed_description>Further study detail provide Centre Oscar Lambret</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Metastatic ocular melanoma Age &gt; = 18 year old Measurable metastasis &gt; = 10 mm accord RECIST criterion PSWHO &lt; = 1 IK &gt; 70 percent Normal hepatic function PNN &gt; 1500/mm3 , platelet &gt; = 100 000/mm3 Contraception Informed consent sign Patient two prior line systemic treatment ( chemotherapy , immunotherapy association ) Other evolutive neoplasic disease Severe hepatic insufficiency Severe renal insufficiency Somatic psychiatric comorbidity incompatible protocol Leptomeningeal cerebral metastatic dissemination Pregnant lactate woman Other antitumoral treatment Patient participate another clinical trial experimental drug Known hypersensitivity Imatinib one excipients Resecable single metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Ocular , Metastatic melanoma</keyword>
</DOC>